On second thought, AbbVie's new arthritis drug not so costly, ICER says

A re-evaluation of Rinvoq makes it look like a better value, although the group's estimate says it offers "marginal clinical benefit" compared to Humira.

By Jonathan Gardner • Oct. 11, 2019

Parexel partners with Datavant on real-world data

The agreement reflects a growing hunger among drug developers for real-world data and analytics services.

By Kristin Jensen • Oct. 10, 2019

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Native ISI rich media: A prescription for the ultimate digital pharma campaign

In a rapidly growing industry, solutions exist that meet the two key criteria of a successful pharmaceutical campaign: visibility and compliance.

Oct. 10, 2019

HHS pitches sweeping revamp of Anti-Kickback Statute, Stark Law

Pharmaceutical companies are excluded from the changes, but HHS head Alex Azar said work is ongoing on separate regulations for the drug industry.

By David Lim • Oct. 9, 2019

With new report, ICER puts itself at center of drug pricing storm

Pharma price hikes added billions of dollars to U.S. spending in 2017 and 2018. For seven top drugs, the watchdog found those increases came with little new clinical evidence in support. 

By Ned Pagliarulo • Updated Oct. 8, 2019

Eylea casts a shadow over Novartis' latest approval

At least one analyst sees few reasons for doctors to use Novartis' Beovu in place of the Regeneron eye drug, citing a less-than-ideal label.

By Jacob Bell • Oct. 8, 2019

Buttigieg targets pharma in aggressive plan to lower drug prices

The presidential hopeful supports several policies, such as direct drug price negotiation, that feature in legislation proposed by House Democrats. 

By Ned Pagliarulo • Oct. 7, 2019

Gilead's follow-on PrEP drug gets broad label, but with a notable exclusion

The FDA approved Descovy to prevent HIV infection in adults and adolescents, but not for cisgender women.

By Jacob Bell • Oct. 4, 2019

How to relaunch your healthcare website in the new era of search

Patient search behavior has changed. Here's what to expect when relaunching your healthcare website.

Oct. 4, 2019

Gene therapy stocks have taken a beating. Their recovery may be slow

Share prices of at least 26 gene therapy biotechs were down on the year in October, a sign of some investor uncertainty on how the drugs will be sold.

By Jacob Bell • Oct. 3, 2019

J&J paying $20M to settle Ohio opioid suits

The pharma giant joins Endo, Mallinckrodt and Allergan in reaching a settlement deal with Cuyahoga and Summit counties in Ohio.

By Ned Pagliarulo • Oct. 2, 2019

Look beyond ROI to optimize TV campaigns

Don’t leave precious dollars on the table.

By Crossix Solutions • Sept. 30, 2019

AstraZeneca, Merck strengthen lead in PARP drug class

AbbVie appears back on track with rival veliparib, but until it's approved Lynparza looks set to be a preferred option in first-line ovarian cancer.

By Jonathan Gardner • Sept. 28, 2019

Top Pelosi aide to payers: Help us defeat Big Pharma

Wendell Primus' pitch sparked debate between policy experts and industry representatives Monday at AHIP's annual conference.

By Samantha Liss • Sept. 24, 2019

Public health alert or legal advertising? It can be hard to tell.

"It's whack-a-mole; it really is," Aviva Wein, J&J's assistant general counsel for product liability, said of the increasing number of ads targeting devices.

By Dana Elfin • Sept. 24, 2019

States pull back curtain on drug prices, to uncertain effect

A newly enacted law in Colorado requires pharma companies inform doctors of list prices, as well as the names of three generics in the same treatment class. 

By Ned Pagliarulo • Sept. 23, 2019

Does disclosure of pharma payments harm patient trust in doctors?

A counterintuitive finding raises questions about how transparency can be better managed, University of Pennsylvania researcher Genevieve Kanter told BioPharma Dive.

By Andrew Dunn • Sept. 23, 2019

Is the future of diabetes treatment better drugs or better care?

Drug manufacturers are trying to push the boundaries of glucose control, but cost concerns could rein in ambitions.

By Jonathan Gardner • Sept. 23, 2019

Regulatory barriers limit alternative state drug payment models

Forced to balance higher costs with public health goals, more states are looking at alternative payment models for prescription drugs in Medicaid.

By Samantha Liss • Sept. 18, 2019

J&J finds competitive edge with latest Erleada approval

The advantage may be short-lived, however, as a rival prostate cancer drug from Pfizer could notch a similar approval in the fourth quarter.

By Jacob Bell • Sept. 18, 2019

Vertex makes headway in UK reimbursement

Scotland has agreed to cover two Vertex drugs, Orkambi and Symkevi, which may bode well for resolving a dispute over the company's prices.

By Jacob Bell • Sept. 12, 2019

Survey suggests Ionis is losing battle against Pfizer and Alnylam

Physician preferences between the company's respective drugs appear to be emerging in the year since Ionis' Tegsedi won approval. 

By Jacob Bell • Sept. 10, 2019

Pharma's reputation among Americans sinks to lowest level in decades: poll

According to Gallup, Americans even view the federal government more favorably than biopharma, which ranks as the most poorly regarded industry.

By Kristin Jensen • Sept. 4, 2019

Novartis secures NICE nod for Luxturna with discount offer

The U.K. cost agency recommended Luxturna after reaching a deal with Novartis, which sells the Spark gene therapy outside the U.S.

By Ned Pagliarulo • Sept. 4, 2019

Skyrizi looks ready to soar after strong launch

Dermatologists expect Skyrizi prescriptions to accelerate, according to a new survey that has some analysts now forecasting $300 million in 2019 sales for the psoriasis drug.

By Jacob Bell • Sept. 4, 2019